Skip to main content
Premium Trial:

Request an Annual Quote

RXi Q1 Loss Rises on Opko Deal Charge


RXi Pharmaceuticals this week reported its first-quarter financial results, posting a sharply increased net loss on a one-time charge associated with its purchase of the RNAi drug assets of Opko Health in early March.

For the three-month period ended March 31, RXi’s net loss was $14.4 million, compared with $1.9 million in the same quarter a year earlier. Driving the loss was a $12.3 million charge related to the fair value of RXi common shares issued to Opko under the companies’ deal (GSN 3/7/2013).

RXi’s revenues were $100,000, versus no revenues in the year-ago period, and reflect money received under government grants.

Research and development spending surged to $13.8 million from $1.2 million, primarily due to the charge associated with the Opko deal, while general and administrative expenses fell $100,000 to $700,000.

At the end of the first quarter, RXi had cash and cash equivalents totaling $19.6 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.